BioSpace News Archive

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the first quarter ended March 31, 2022.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today reported financial results for the first quarter ended March 31, 2022 and provided recent business highlights.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the formation of its scientific advisory board (SAB).

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that it has obtained worldwide exclusive rights to Sanofi’s KY1066, which will be referred to as RLYB331 going forward, a preclinical potentially first-in-class antibody.

Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, announced that company management will be presenting scientific and clinical overviews in three oral presentations at the Allogeneic Cell Therapies Summit 2022 and the 20th Biomed Israel Conference and Exhibition.

Elo Life Systems , a company that is empowering the future of sustainable and healthy food, announced that Todd Rands has been appointed as its new Chief Executive Officer.

Beacon Biosignals, which applies AI to EEG to unlock precision medicine for brain conditions, today announced a partnership with Stratus, the nation’s leading provider of EEG services, to enable expanded clinical trial service capabilities by leveraging Beacon’s machine learning neuroanalytics platform.

VBL Therapeutics announced that it will release first quarter financial results for the period ended March 31, 2022 on Tuesday, May 17 before market open.

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases, reported financial results for the first quarter 2022 and provided a corporate business update.